Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 170INDUSTRY 124NETWORK 4INDIV 4FED 3

Study Type

Observational 3Interventional 1

Sponsor

Conditions

Neoplasms 8Barrett Esophagus 5Myasthenia Gravis 4Breast Neoplasms 4Leiomyoma 3Carcinoma, Hepatocellular 3Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Follicular 2Lung Neoplasms 2Lipoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma in Situ 2Warts 1Vaginosis, Bacterial 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Syphilis 1Sexually Transmitted Diseases 1Retroperitoneal liposarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pilonidal Sinus 1Papillomavirus Infections 1Overweight 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Tacrolimus 2Pyridostigmine Bromide 2Prednisone 2blinatumomab 1Steroids 1Mycophenolic Acid 1Methylprednisolone 1Methotrexate 1Immunosuppressive Agents 1Immunoglobulins, Intravenous 1Cyclosporine 1Cyclophosphamide 1Azathioprine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDIV × Myasthenia Gravis × Clear all
NCT07079020 2025-07-22

Efgartigimod for Consolidation Therapy in gMG

Da, Yuwei, M.D.

Not yet recruiting
130 enrolled

Myasthenia Gravis

NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

NCT04101578 2021-08-23

Clinical Prognosis and Progression of Myasthenia Gravis Patients

Da, Yuwei, M.D.

Unknown
2,000 enrolled

Myasthenia Gravis

NCT04768465 2021-02-24

Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis

Da, Yuwei, M.D.

Unknown
160 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡